CYP2E1 and metabolic dysfunction-associated steatohepatitis: Thus, CYP2E1 polymorphisms that associate with the progression of NAFLD to NASH may possibly trigger the combined detrimental effects of both ROS and RNS, which in combination with toxic metabolites from xenobiotic biotransformation may result in further aggravated liver injury in NAFLD patients.